You are here: Industry Insights > ASD

News List

Exposure to Prenatal Antipsychotics Seems Safe drugs
August 17, 2021
Exposure to prenatal antipsychotics does not appear to be associated with an increased risk for attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), or small for gestational age, according to a study published online Aug. 16.
PAX-101 meaningfully improves core symptoms of autism europeanpharmaceuticalreview
February 25, 2021
In a phase II trial, PAX-101 (IV suramin) significantly improved symptoms in children with moderate to severe autism spectrum disorder (ASD).
MapLight Completes Dosing in Phase 1 Study for Social Deficit in Autism americanpharmaceuticalreview
December 09, 2020
MapLight Therapeutics has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin receptor agonist.
Severity of Autism Symptoms May Vary in Monozygotic Twins drugs
January 02, 2020
Autism spectrum disorder (ASD) is markedly heritable, with probandwise concordance of 96 percent, but there is variation in the severity of symptomatology above the diagnostic threshold ...
Therapix Biosciences Announces Continued Development of Autism Spectrum Disorder Treatment americanpharmaceuticalreview
December 30, 2019
Therapix Biosciences has announced the progression of its RESPECTRUM product candidate into clinical stage. The company plans to initiate a randomized ...
Few Trauma Patients Assessed for Effects of PTSD, Acute Stress drugs
September 20, 2019
Few trauma patients are assessed for or educated about the potential effects of posttraumatic stress disorder (PTSD) or acute stress disorder (ASD) ...
Prenatal Vitamin Intake in Early Pregnancy May Cut Autism Risk drugs
February 28, 2019
Maternal prenatal vitamin intake during the first month of pregnancy is associated with a reduced risk for autism spectrum disorder (ASD) in siblings of children with ASD, according to a study published online Feb. 27 in JAMA Psychiatry....
Stem Cell Medicine Licenses Exosome Technology from Ramot at Tel Aviv University americanpharmaceuticalreview
January 03, 2019
Stem Cell Medicine has licensed an exosomes based technology for the treatment of neurodegenerative and neuropsychiatric indications, specifically, autism spectrum disorder (ASD).....
Q BioMed Announces Partnership with SRI International americanpharmaceuticalreview
December 13, 2018
Q BioMed announced a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001....
Risk Up for Later-Born Siblings of Children With ASD, ADHD drugs
December 11, 2018
Later-born siblings of children with autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD) have an elevated risk of being ....

Previous page 1 2 Next page